Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Virtual Conference
22 févr. 2021 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients
17 févr. 2021 07h30 HE
|
Salarius Pharmaceuticals, Inc.
Seclidemstat safety profile affirmed; Recommended Phase 2 dose established Demonstrated preliminary evidence of seclidemstat drug activity in subset of Ewing-related sarcoma patients HOUSTON, Feb. ...
Salarius Pharmaceuticals to Present at BIO CEO & Investor Digital Conference
16 févr. 2021 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid...
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
21 janv. 2021 08h05 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference
15 janv. 2021 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals Receives Second Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas
13 janv. 2021 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals to Participate in Biotech Showcase Digital and BIO @ JPM During "J.P. Morgan Week 2021"
22 déc. 2020 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid...
Salarius Announces Exercise Of Warrants For $3.5 Million Of Gross Proceeds To Be Used For Ongoing Development Of Seclidemstat
11 déc. 2020 11h32 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals Receives First Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas
10 déc. 2020 09h28 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals to Participate in A.G.P.’s Virtual Healthcare Symposium
17 nov. 2020 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...